*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 104-88-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 104-88-1 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Citations Show More

Design, Synthesis, and Computational Evaluation of 3, 4-Dihydroquinolin-2 (1H)-One Analogues as Potential VEGFR2 Inhibitors in Glioblastoma Multiforme

Buhlak, Shafeek ; Abad, Nadeem ; Akachar, Jihane ; Saffour, Sana ; Kesgun, Yunus ; Dik, Sevval , et al.

DOI: 10.3390/ph18020233 Pharmaceuticals,2025,18(2):233.

Abstract: Background/Objectives: Glioblastoma multiforme (GBM), an aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment due to its resistance to current therapies and poor prognosis. This study aimed to synthesise and evaluate 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, designed to enhance druggability and solubility, and to investigate their potential as VEGFR2 inhibitors for GBM treatment. Methods: The synthesised compounds were analysed using in silico methods, including molecular docking and dynamics studies, to assess their interactions with key residues within the VEGFR2 binding pocket. In vitro evaluations were performed on U87-MG and U138-MG GBM cell lines using MTT assays to determine the IC50 values of the compounds. Results: Among the tested compounds, 4u (IC50 = 7.96 µM), 4t (IC50 = 10.48 µM), 4m (IC50 = 4.20 µM), and 4q (IC50 = 8.00 µM) demonstrated significant antiproliferative effects against both the U87-MG and U138-MG cell lines. These compounds exhibited markedly higher efficacy compared to temozolomide (TMZ), which showed IC50 values of 92.90 µM and 93.09 µM for U87-MG and U138-MG, respectively. Molecular docking and dynamics studies confirmed strong interactions between the compounds and VEGFR2 kinase, supporting their substantial anti-cancer activity. Conclusions: This study highlights the promising potential of 3,4-dihydroquinolin-2(1H)-one analogues, particularly 4m, 4q, 4t, and 4u, as VEGFR2-targeting therapeutic agents for GBM treatment. Further detailed research is warranted to validate and expand upon these findings.

Keywords: glioblastoma multiforme ; 3,4-dihydroquinolin-2(1H)-one ; therapeutic efficacy ; molecular docking ; molecular dynamics ; VEGFA–VEGFR2 pathway ; anti-cancer

Purchased from AmBeed: 613-45-6 ; 98-03-3 ; 54197-66-9 ; 104-88-1

Exploring the Volatility, Phase Transitions, and Solubility Properties of Five Halogenated Benzaldehydes

Almeida, Ana RRP ; Pinheiro, Bruno DA ; León, Gastón P ; Postolnyi, Bogdan ; Araújo, João P ; Monte, Manuel JS

DOI: 10.3390/molecules30071551 Molecules,2025,30(7):1551.

Abstract: Halogenated benzaldehydes possess unique chemical properties that render them valuable in pharmaceutical synthesis, pesticide formulation, and dye production. However, thorough thermodynamic data for these compounds remain scarce. This study aims to fill this knowledge gap by investigating key physical properties of several halogenated benzaldehydes, namely 4-chlorobenzaldehyde, 4-bromobenzaldehyde, 2,3-dichlorobenzaldehyde, 2,4-dichlorobenzaldehyde, and 2,6-dichlorobenzaldehyde. The physical properties determined in this study include volatility, phase transitions, and water solubility, all of which are crucial for predicting the environmental fate of these compounds. The vapor pressures of both crystalline and liquid phases were measured using a reliable static method, allowing for the determination of standard molar enthalpies, entropies, and Gibbs energies of sublimation and vaporization, as well as their triple points. The melting temperature and molar enthalpy, along with the isobaric molar heat capacity of the crystalline phase, were assessed using differential scanning calorimetry. Water solubility was evaluated at 25◦C through the saturation shake-flask method, complemented by ultra-violet visible spectroscopy. By combining sublimation and solubility data, additional properties such as Gibbs energies of hydration and Henry's law constants were derived. The experimental results were integrated into existing databases, enhancing the predictive models for properties including melting temperature, vapor pressure, solubility, Gibbs energy of hydration, and Henry's constant. These findings significantly improve the environmental modeling capabilities, providing valuable insights into the mobility and fate of halogenated benzaldehydes in various environmental contexts.

Keywords: 4-chlorobenzaldehyde ; 4-bromobenzaldehyde ; 2,3-dichlorobenzaldehyde ; 2,4-dichlorobenzaldehyde ; 2,6-dichlorobenzaldehyde ; volatility ; phase transitions ; solubility

Purchased from AmBeed: 104-88-1

Design and synthesis of imidazo[1,2-a]pyridine-chalcone conjugates as antikinetoplastid agents

Agarwal, Devesh S. ; Beteck, Richard M. ; Ilbeigi, Kayhan ; Caljon, Guy ; Legoabe, Lesetja J. ;

DOI: 10.1111/cbdd.14400 PubMed ID: 37994272 Chem. Biol. Drug Des.,2024,103(1):e14400.

Abstract: A library of imidazo[1,2-a]pyridine-appended chalcones were synthesized and characterized using 1H NMR,13C NMR and HRMS. The synthesized analogs were screened for their antikinetoplastid activity against Trypanosoma cruzi, Trypanosoma brucei brucei, Trypanosoma brucei rhodesiense and Leishmania infantum. The analogs were also tested for their cytotoxicity activity against human lung fibroblasts and primary mouse macrophages. Among all screened derivatives, (E)-N-(4-(3-(2-chlorophenyl)acryloyl)phenyl)imidazo[1,2-a]pyridine-2-carboxamide was found to be the most active against T. cruzi and T. b. brucei exhibiting IC50 values of 8.5 and 1.35 μM, resp. Against T. b. rhodesiense, (E)-N-(4-(3-(4-bromophenyl)acryloyl)phenyl)imidazo[1,2-a]pyridine-2-carboxamide was found to be the most active with an IC50 value of 1.13 μM. All synthesized active analogs were found to be non-cytotoxic against MRC-5 and PMM with selectivity indexes of up to more than 50.

Keywords: antikinetoplastid ; chalcone ; drug likeliness properties ; imidazo[1,2-a]pyridine ; neglected tropical diseases (NTDs) ; Trypanosoma brucei brucei ; Trypanosoma brucei rhodesiense

Purchased from AmBeed: 613-45-6 ; 587-04-2 ; 6287-38-3 ; 1122-91-4 ; 64951-08-2 ; 99-92-3 ; 99-92-3 ; 456-48-4 ; 555-16-8 ; 94-41-7 ; 104-88-1 ; 1113-59-3 ; 459-57-4 ; 529-20-4 ; 1113-59-3

Are β-Lactones Involved in Carbon-Based Olefination Reactions?

Jan Nowak ; Michał Tryniszewski ; Michał Barbasiewicz ;

DOI: 10.1055/a-2268-4386 Synlett,2024,35(10):1190-1194.

Abstract: Heteroatom-based olefinating reagents (e.g., organic phosphonates, sulfonates, etc.) are used to transform carbonyl compounds into alkenes, and their mechanism of action involves aldol-type addition, cyclization, and fragmentation of four-membered ring intermediates. We have developed an analogous process using ethyl 1,1,1,3,3,3-hexafluoroisopropyl methylmalonate, which converts electrophilic aryl aldehydes into α-methylcinnamates in up to 70% yield. The reaction plausibly proceeds through the formation of β-lactone that spontaneously decarboxylates under the reaction conditions. The results shed light on the Knoevenagel–Doebner olefination, for which decarboxylative anti-fragmentation of aldol-type adducts is usually considered.

Keywords: olefination ; carbonyl compounds ; reaction mechanism ; lactones ; malonates ; Knoevenagel ; Doebner reaction

Purchased from AmBeed: 587-04-2 ; 609-08-5 ; 29166-72-1 ; 99-61-6 ; 555-16-8 ; 104-88-1 ; 6674-22-2

Nitrothiazole-Thiazolidinone Hybrids: Synthesis and in Vitro Antimicrobial Evaluation

Dylan Hart ; Lesetja J. Legoabe ; Omobolanle J. Jesumoroti ; Audrey Jordaan ; Digby F. Warner ; Rebecca Steventon , et al.

DOI: 10.1002/cbdv.202200729 PubMed ID: 36102043 Chem. Biodivers.,2022,19(11):e202200729.

Abstract: Herein we report the synthesis of novel compounds inspired by the antimicrobial activities of nitroazole and thiazolidin-4-one based compounds reported in the literature. Target compounds were investigated in vitro for antitubercular, antibacterial, antifungal, and overt cell toxicity properties. All compounds exhibited potent antitubercular activity. Most compounds exhibited low micromolar activity against S. aureus and C. albicans with no overt cell toxicity against HEK-293 cells nor haemolysis against human red blood cells. Notably, compound 3b exhibited low to sub-micromolar activities against Mtb, MRSA, and C. albicans. 3b showed superior activity (0.25 μg/ml) against MRSA compared to vancomycin (1 μg/ml).

Purchased from AmBeed: 613-45-6 ; 121-66-4 ; 587-04-2 ; 104-87-0 ; 6287-38-3 ; 552-89-6 ; 456-48-4 ; 830-79-5 ; 555-16-8 ; 104-88-1 ; 591-31-1 ; 3132-99-8 ; 446-52-6 ; 459-57-4 ; 529-20-4 ; 123-08-0 ; 100-52-7 ; 349121-09-1 ; 89-98-5

Product Details of [ 104-88-1 ]

CAS No. :	104-88-1
Formula :	C₇H₅ClO
M.W :	140.57
SMILES Code :	O=CC1=CC=C(Cl)C=C1
MDL No. :	MFCD00003379
InChI Key :	AVPYQKSLYISFPO-UHFFFAOYSA-N
Pubchem ID :	7726

Safety of [ 104-88-1 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H303-H312-H318-H411
Precautionary Statements:	P273-P280-P302+P352+P312-P305+P351+P338+P310-P312-P362+P364-P391-P501
Class:	9
UN#:	3077
Packing Group:	Ⅲ

Computational Chemistry of [ 104-88-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	9
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	1
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	36.84
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	17.07 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.6
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.1
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.15
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.05
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.64
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.11

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.46
Solubility	0.485 mg/ml ; 0.00345 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.09
Solubility	1.15 mg/ml ; 0.00815 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.94
Solubility	0.163 mg/ml ; 0.00116 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.67 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.0

Application In Synthesis of [ 104-88-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 104-88-1 ]
Downstream synthetic route of [ 104-88-1 ]

[ 104-88-1 ] Synthesis Path-Upstream 1~11

1
[ 104376-24-1 ]
[ 104-88-1 ]
[ 7295-50-3 ]

References: [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 48, p. 11465 - 11469.

2
[ 624-45-3 ]
[ 104-88-1 ]
[ 73257-49-5 ]

Yield	Reaction Conditions	Operation in experiment
84%	With ammonium acetate In neat (no solvent) at 55℃; for 3 h; Green chemistry	General procedure: Polyhydroquinolines and DihydropyridinesA mixture of aldehyde (1 mmol), β-dicarbonyl compound (1or 2 mmol), NH4OAc (2.5 mmol), dimedone (1 mmol, whenused), and SBA-15/NHSO3H (5 molpercent) was stirred at 55 °C.After complete disappearance of starting material asindicated by TLC, the resulting mixture was diluted with hotEtOAc (10 mL) and filtered. The catalyst was completelyrecovered from the residue

References: [1] Synlett, 2014, vol. 25, # 19, p. 2753 - 2756.

3
[ 631-61-8 ]
[ 104-88-1 ]
[ 105-45-3 ]
[ 73257-49-5 ]

Yield	Reaction Conditions	Operation in experiment
96%	With iron supported on copper/Zeolite Socony Mobil-5 nanocatalyst In water at 20℃; Sonication	General procedure: In a typical experiment, aromatic aldehyde (1 mmol), bketoester(2 mmol), ammonium acetate (1 mmol), and Fe-Cu/ZSM-5 (3 wtpercent) in 2 ml water were introduced in a 20-mL heavy-walled pear-shaped two-necked flask with nonstandard-tapered outer joint. The flask was attached to a12-mm tip diameter probe, and the reaction mixture was sonicated at ambient temperature at 20 percent power of the processor. After completion of the reaction (monitored byTLC, within 5–8 min), the solid product was filtered,washed with water and ethanol, dried, and recrystallized from ethanol. The supported reagent was washed thrice with water and ethanol and dried under vacuum before reuse.

References: [1] Journal of the Iranian Chemical Society, 2016, vol. 13, # 2, p. 267 - 277.

4
[ 104-88-1 ]
[ 105-45-3 ]
[ 73257-49-5 ]

Yield	Reaction Conditions	Operation in experiment
95%	at 80℃; for 0.3 h;	General procedure: A mixture of the alkyl or aryl aldehyde (1 mmol), -dicarbonyl(2 mmol) and ammonium acetate (1.5 mmol) in the presence ofFe3O4NPs (0.024 g, equal to 10 molpercent) was heated at 80C, withstirring. The progress of the reaction was monitored by TLC (elu-ent: EtOAc:n-hexane). After completion of the reaction, the mixturewas cooled to room temperature and then ethanol was added tothe resulting mixture and separated Fe3O4NPs by a normal mag-net. After evaporation of solvent, the solid product was filtered andrecrystallized from ethanol to give the pure products in 72–95percentyields based on the starting aldehyde.
95%	With C₂₃H₃BF₁₆N₂O; ammonium acetate In toluene at 100℃; for 10 h;	In a 100 mL single-necked flask, 0.01 molpercent of Lewis acid-base bifunctional catalyst I was added (where Rf = CF3R1,R2, R3, R4, R5, R6 = F), 0.1 mol of p-chlorobenzaldehyde (R7 = 4-Cl-Ph), 0.1 mol of methyl acetoacetate (R8 = Me;Me), 0.1 mol of ammonium acetate, 10 mL of toluene, and the reaction was stirred at 100 ° C for 10 hours. TLC followed the reaction to complete the reaction. anti-The yield of the product II (R7 = 4-Cl-Ph; R8 = Me; R9 = Me) was 95percent; the catalyst system was reused 10 timesAfter its catalytic performance did not decline
94%	for 2.25 h; Heating; Green chemistry	General procedure: A mixture of aldehyde 1 (1 mmol), 1,3-dicarbonyl compound 2 (2 mmol), and nitrogen source 3 (3 mmol) were mixed and heated in the presence of a low-melting sugar mixture.The progress of the reaction was monitored by thin-layer chromatography (TLC) using n-hexane–ethyl acetate (7:3) as the solvent system. The Rf values of the product spots ranged from 0.5 to 0.6. After completion of the reaction, water was added to the reaction mixture to obtain the solid product as a precipitate. In cases where the product was obtained as a melt, several washings with water followed by bicarbonate solution gave crystalline products. The solids were filtered and washed with cold water. In most of the cases, the product obtained was pure, and when impure, the product was recrystallized from hot ethanol. Further two products were obtained as oils (Table 5, entries 4w and 4x). These products were extracted with ethyl acetate and dried over anhydrous Na2SO4. Evaporation of the solvent gave the pure product as an oil.

91%	at 100℃; for 0.25 h; Green chemistry	General procedure: To a glassy reactor equipped with a magnetic stir bar, amixture of aromatic aldehyde (1.0 mmol), β-keto ester(2 mmol), ammonium acetate (1.5 mmol) and n-Fe₃O₄(at)ZrO₂/HPW (0.003 g, 15 mol percent) was added. The reactorwas put in an oil bath with the temperature of 100 °C andthe reaction was carried out under solvent-free condition.The progress of the reaction was monitored using TLCplates. When the reaction was completed, the mixture wasallowed to cool to room temperature. Afterwards, the mixturewas triturated with 5mL ethyl acetate and the catalystwas separated by the help of an external magnet. Then thesolvent was evaporated and the crude product was recrystallizedfrom EtOH/H₂O to offer the pure product.
90%	With uranyl nitrate hexahydrate; ammonium acetate In ethanol at 20℃; for 0.416667 h; Sonication	General procedure: To a solution of aldehyde (1.0 mmol), ethyl/methyl acetoacetate/acetylacetone (2.0 mmol) and ammonium acetate (1.0 mmol) in ethanol (3 mL), uranyl nitrate (10 molpercent) was added and the resultant reaction mixture was sonicated at room temperature for the required time (Table 1). The progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was poured into crushed ice. The obtained solid was filtered, washed thoroughly with water, dried, and purified by recrystallisation in ethanol.

References: [1] RSC Advances, 2014, vol. 4, # 100, p. 56658 - 56664.
[2] Tetrahedron Letters, 2010, vol. 51, # 8, p. 1187 - 1189.
[3] Advanced Synthesis and Catalysis, 2012, vol. 354, # 10, p. 2001 - 2008.
[4] Journal of Molecular Catalysis A: Chemical, 2014, vol. 382, p. 99 - 105.
[5] Patent: CN107141249, 2017, A, . Location in patent: Paragraph 0114; 0115.
[6] Synthetic Communications, 2016, vol. 46, # 24, p. 1989 - 1998.
[7] RSC Advances, 2014, vol. 4, # 21, p. 10514 - 10518.
[8] Journal of the Indian Chemical Society, 2009, vol. 86, # 9, p. 996 - 1000.
[9] New Journal of Chemistry, 2018, vol. 42, # 15, p. 12539 - 12548.
[10] Journal of Heterocyclic Chemistry, 2008, vol. 45, # 3, p. 737 - 739.
[11] Catalysis Letters, 2017, vol. 147, # 6, p. 1551 - 1566.
[12] Chemical Communications, 2011, vol. 47, # 32, p. 9230 - 9232.
[13] Research on Chemical Intermediates, 2015, vol. 41, # 9, p. 6877 - 6883.
[14] Journal of the Chinese Chemical Society, 2016, vol. 63, # 4, p. 336 - 344.
[15] Synthesis, 2007, # 18, p. 2835 - 2838.
[16] Organic Preparations and Procedures International, 2012, vol. 44, # 2, p. 153 - 158.
[17] Synthetic Communications, 2004, vol. 34, # 23, p. 4349 - 4357.
[18] Synthetic Communications, 2009, vol. 39, # 11, p. 1957 - 1965.

5
[ 105025-71-6 ]
[ 104-88-1 ]
[ 73257-49-5 ]

References: [1] Journal of Materials Chemistry A, 2013, vol. 1, # 37, p. 11210 - 11220.

6
[ 104-88-1 ]
[ 14205-39-1 ]
[ 105-45-3 ]
[ 73257-49-5 ]

References: [1] Tetrahedron Letters, 1995, vol. 36, # 44, p. 8083 - 8086.

7
[ 67-56-1 ]
[ 104-88-1 ]
[ 72324-39-1 ]
[ 73257-49-5 ]

References: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 5, p. 745 - 747.

8
[ 104-88-1 ]
[ 105-45-3 ]
[ 14205-39-1 ]
[ 73257-49-5 ]

References: [1] Organic Process Research and Development, 2001, vol. 5, # 4, p. 452 - 455.

9
[ 104-88-1 ]
[ 105-45-3 ]
[ 73257-49-5 ]

References: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1995, vol. 34, # 7, p. 652 - 653.

10
[ 674-82-8 ]
[ 67-56-1 ]
[ 104-88-1 ]
[ 73257-49-5 ]

References: [1] Synthesis, 2010, # 23, p. 4057 - 4060.

11
[ 392-83-6 ]
[ 104-88-1 ]
[ 198205-95-7 ]

References: [1] Organic Letters, 2012, vol. 14, # 17, p. 4606 - 4609.

[ 104-88-1 ] Synthesis Path-Downstream 1~30

1
[ 98-98-6 ]
[ 104-88-1 ]
[ 27652-89-7 ]

References: [1]Chemistry - A European Journal,2014,vol. 20,p. 4156 - 4162.
[2]Journal of the American Chemical Society,1949,vol. 71,p. 887,889.

2
[ 24686-78-0 ]
[ 104-88-1 ]
1-benzoyl-3,5-bis-(4-chloro-benzylidene)-piperidin-4-one [ No CAS ]

References: [1]Journal of the American Chemical Society,1949,vol. 71,p. 901,904.

3
[ 104-88-1 ]
[ 1809-21-8 ]
[ 1694-06-0 ]
C₂₁H₂₈ClN₂O₆PS [ No CAS ]

References: [1]Phosphorus, Sulfur and Silicon and the Related Elements,1997,vol. 122,p. 261 - 267.

4
[ 104-88-1 ]
[ 868-85-9 ]
[ 1694-06-0 ]
C₁₇H₂₀ClN₂O₆PS [ No CAS ]

References: [1]Phosphorus, Sulfur and Silicon and the Related Elements,1997,vol. 122,p. 261 - 267.

5
[ 104-88-1 ]
[ 762-04-9 ]
[ 1694-06-0 ]
C₁₉H₂₄ClN₂O₆PS [ No CAS ]

References: [1]Phosphorus, Sulfur and Silicon and the Related Elements,1997,vol. 122,p. 261 - 267.

6
[ 1809-20-7 ]
[ 104-88-1 ]
[ 1694-06-0 ]
C₂₁H₂₈ClN₂O₆PS [ No CAS ]

References: [1]Phosphorus, Sulfur and Silicon and the Related Elements,1997,vol. 122,p. 261 - 267.

7
[ 57497-39-9 ]
[ 104-88-1 ]
[ 40117-30-4 ]

References: [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 3995 - 3998.
[2]Chemical Communications,2001,p. 1968 - 1969.

8
[ 6972-82-3 ]
[ 104-88-1 ]
[ 61885-33-4 ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 347 - 356.

9
[ 21109-25-1 ]
[ 104-88-1 ]
[ 943188-13-4 ]

References: [1]Tetrahedron,2007,vol. 63,p. 4983 - 4989.

10
[ 6642-31-5 ]
[ 538-28-3 ]
[ 104-88-1 ]
[ 1008438-27-4 ]

References: [1]Heterocycles,2008,vol. 75,p. 87 - 93.

11
[ 104-88-1 ]
[ 66491-03-0 ]
[ 1316701-96-8 ]

Yield	Reaction Conditions	Operation in experiment
16%	With sodium tris(acetoxy)borohydride; acetic acid; In dichloromethane; at 20℃;	Example 2) l-MethyI-lH-pyrazoIe-3-sulfonic acid (4-chloro-benzyl)-(2-ethyl-l- oxo-1 ,2,3,4-tetrahydro-isoquinolin-7-yl)-amide (METHOD B)i) 7-Benzylamino-3,4-dihydro-2H-isoquinolin-l-one Sodium triacetoxyborohydride (1.29 g, 6.16 mmol) was added to a stirred solution of 7-amino-3,4-dihydro-2H-isoquinolin-l-one (500 mg, 3.08 mmol), 4- chlorobenzaldehyde (431 mg, 3.0S mmol) and acetic acid (183 mul, 3.08 mmol) in anhydrous dichloromethane (25 ml) at room temperature. The reaction was stirred overnight and quenched with the addition of water. The organic phase was separated, washed with brine, then dried (MgSO4) and evaporated in vacuo. The resulting residue was purified by flash column chromatography (50% ethyl acetate in dichloromethane) to yield the title compound as a pale yellow solid (287 mg, 16%). HPLC retention time 4.09min. Mass spectrum (ES+) m/z 287 (M+H).

References: [1]Patent: WO2010/139953,2010,A1 .Location in patent: Page/Page column 35.

12
[ 88333-03-3 ]
[ 104-88-1 ]
[ 42182-27-4 ]
[ 1311992-26-3 ]

References: [1]Journal of the American Chemical Society,2011,vol. 133,p. 10058 - 10061.

13
[ 104-88-1 ]
[ 42182-27-4 ]
[ 1333247-51-0 ]

References: [1]Journal of the American Chemical Society,2011,vol. 133,p. 10058 - 10061.

14
[ 104-88-1 ]
[ 42182-27-4 ]
[ 2769-72-4 ]
[ 1032186-22-3 ]

References: [1]Journal of the American Chemical Society,2011,vol. 133,p. 10058 - 10061.

15
[ 1314538-55-0 ]
[ 104-88-1 ]
[ 156866-52-3 ]

References: [1]Organic Letters,2011,vol. 13,p. 3956 - 3959.

16
[ 67-56-1 ]
[ 104-88-1 ]
[ 13726-16-4 ]

References: [1]Journal of the Indian Chemical Society,2011,vol. 88,p. 727 - 730.

17
[ 110-86-1 ]
[ 104-88-1 ]
[ 27652-89-7 ]

References: [1]Chemical Communications,2013,vol. 49,p. 2124 - 2126.

18
[ 1006-33-3 ]
[ 104-88-1 ]
C₁₅H₁₁BrClFO₂ [ No CAS ]

References: [1]Journal of Organic Chemistry,2013,vol. 78,p. 2736 - 2741.

19
[ 57497-39-9 ]
[ 104-88-1 ]
[ 40117-30-4 ]

References: [1]ACS Catalysis,2016,vol. 6,p. 84 - 91.
[2]Journal of Medicinal Chemistry,2013,vol. 56,p. 6531 - 6535.
[3]Journal of Organic Chemistry,2015,vol. 80,p. 7333 - 7339.

20
[ 109-04-6 ]
[ 104-88-1 ]
[ 27652-89-7 ]

References: [1]Organic and Biomolecular Chemistry,2015,vol. 13,p. 10681 - 10690.

21
[ 845267-78-9 ]
[ 3325-11-9 ]
[ 104-88-1 ]
tert-butyl 11-(4-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-1H-[1,2,3]triazolo[4′,5′:3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate [ No CAS ]

References: [1]Heterocyclic Communications,2015,vol. 21,p. 377 - 380.

22
[ 104-88-1 ]
[ 78364-55-3 ]
2-(2-(4-chlorobenzylidene)hydrazino)-6-fluorobenzothiazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
79%	With acetic acid; In ethanol; at 80℃; for 0.166667h;Microwave irradiation;	General procedure: A mixture of compound 2 (0.0549 g, 0.0003 mol), the appropriate aromatic aldehyde (0.00033 mol) and glacial acetic acid (0.1 mL) in ethanol (5 mL) was heated under microwave (20 W) at 80 °C for 10 min. On cooling, the precipitated solid was collected by filtration, washed with water, dried and crystallized to give compounds 3-29.
	In ethanol; at 70 - 80℃; for 3h;	General procedure: The mixture of <strong>[78364-55-3]6-fluoro-2-hydrazinylbenzo[d]thiazole</strong> (2) (0.01 mol) and benzalde-hyde/substituted benzaldehyde (0.01 mol) was reuxed in ethanol (15 ml) at 70?80 °C for 3 h. The separated product obtained was ltered off, washed withdistilled water and recrystallized from methanol to give the correspondinghydrazone. The product obtained was further dissolved in acetic acid (20 ml) atroom temperature followed by the addition of sodium acetate (0.5 g). Bromine(2 mmol) in acetic acid (10 ml) was added dropwise to the reuxing reactionmixture. After 1 h, the mixture was poured onto crushed ice (100 g). The precipitateobtained was ltered off and crystallized from ethanol-dimethylformamide (1:1) togive crystals of (3a?3t).

References: [1]Chinese Chemical Letters,2016,vol. 27,p. 380 - 386.
[2]Research on Chemical Intermediates,2016,vol. 42,p. 8329 - 8344.

23
[ 64837-53-2 ]
[ 104-88-1 ]
5-(4-chlorobenzylamino)-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
44 mg	With sodium tris(acetoxy)borohydride; trifluoroacetic acid; In isopropyl alcohol; at 20 - 70℃; for 18h;	A suspension of 5-amino-[1 ,3,4]thiadiazole-2-carboxylic acid ethyl ester (0.30 g, 1 .75 mmol), TFA (0.27 mL, 3.50 mmol), 4-chlorobenzaldehyde (0.27 g, 1 .93 mmol) and sodium triacetoxyborohydride (0.45 g, 2.10 mmol) in isopropanol (3.5 mL) was stirred at room temperature for 2 hours and then at 70°C for 1 6 hours. After this time the reaction mixture wasconcentrated under reduced pressure and purified by flash column chromatography, eluting with EtOAc/cyclohexane (0-50percent) to afford the title compound (44 mg). LCMS method: Method 3, RT: 4.81 mm, Ml: 298 [M+1] 1H NMR (500 MHz, CDCI3) O 7.32 (d, 2H), 7.29 (d, 2H), 4.53 (5, 2H), 4.41 (q, 2H), 1 .39 (t, 3H)

References: [1]Patent: WO2016/124938,2016,A1 .Location in patent: Paragraph 00430-00432.

24
[ 13195-64-7 ]
[ 104-88-1 ]
[ 66521-66-2 ]
(+)-di-isopropyl 2-((4-chlorophenyl)((4-(pyridin-3-yl)pyrimidin-2-yl)amino)methyl)malonate [ No CAS ]